Related Experiment Video

Updated: Jun 2, 2026

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies
09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis

Pipsa Saharinen1, Lauri Eklund, Kristina Pulkki

  • 1Molecular/Cancer Biology, Research Programs Unit, Biomedicum Helsinki, P.O.B. 63, (Haartmaninkatu 8), FIN-00014, University of Helsinki, Finland.

Trends in Molecular Medicine
|April 13, 2011
PubMed

Insights

New antiangiogenic therapies targeting VEGF-VEGFR pathways are needed due to resistance. Angiopoietin growth factors and Tie receptors offer promising alternative targets for anti-cancer treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Solid tumors depend on blood and lymphatic vessels for growth and metastasis.
  • Antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF)-VEGF receptor (VEGFR)-2 pathway have been approved but show limited clinical benefit due to resistance.
  • Novel therapeutic strategies are essential to overcome treatment resistance and improve patient outcomes.

Purpose of the Study:

  • To explore novel therapeutic targets for antiangiogenic and antilymphangiogenic therapies.
  • To discuss the potential of VEGF-VEGFR family members and angiopoietin growth factors/Tie receptors as targets.

Main Methods:

  • Review of current literature on angiogenesis and lymphangiogenesis.
  • Analysis of the VEGF-VEGFR and angiopoietin-Tie signaling pathways.
  • Discussion of potential therapeutic strategies targeting these pathways.

Main Results:

  • Limited efficacy and resistance observed with current anti-VEGF-VEGFR therapies.
  • Identification of angiopoietin growth factors and their Tie receptors as potential alternative targets.
  • VEGF-VEGFR family members and angiopoietin-Tie signaling represent promising avenues for novel anti-cancer treatments.

Conclusions:

  • Current antiangiogenic therapies have limitations, necessitating the exploration of new targets.
  • Angiopoietin growth factors and Tie receptors present viable targets for developing novel antiangiogenic and antilymphangiogenic treatments.
  • Targeting these pathways could lead to improved therapeutic outcomes in cancer treatment.

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...